Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Loading...
Embargo End Date
ICR Authors
Authors
Doki, Y
Ajani, JA
Kato, K
Xu, J
Wyrwicz, L
Motoyama, S
Ogata, T
Kawakami, H
Hsu, C-H
Adenis, A
El Hajbi, F
Di Bartolomeo, M
Braghiroli, MI
Holtved, E
Ostoich, SA
Kim, HR
Ueno, M
Mansoor, W
Yang, W-C
Liu, T
Bridgewater, J
Makino, T
Xynos, I
Liu, X
Lei, M
Kondo, K
Patel, A
Gricar, J
Chau, I
Kitagawa, Y
CheckMate 648 Trial Investigators
Ajani, JA
Kato, K
Xu, J
Wyrwicz, L
Motoyama, S
Ogata, T
Kawakami, H
Hsu, C-H
Adenis, A
El Hajbi, F
Di Bartolomeo, M
Braghiroli, MI
Holtved, E
Ostoich, SA
Kim, HR
Ueno, M
Mansoor, W
Yang, W-C
Liu, T
Bridgewater, J
Makino, T
Xynos, I
Liu, X
Lei, M
Kondo, K
Patel, A
Gricar, J
Chau, I
Kitagawa, Y
CheckMate 648 Trial Investigators
Document Type
Journal Article
Date
Date Accepted
2022-02-03
Abstract
<h4>Background</h4>First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma.<h4>Methods</h4>In this open-label, phase 3 trial, we randomly assigned adults with previously untreated, unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma in a 1:1:1 ratio to receive nivolumab plus chemotherapy, nivolumab plus the monoclonal antibody ipilimumab, or chemotherapy. The primary end points were overall survival and progression-free survival, as determined by blinded independent central review. Hierarchical testing was performed first in patients with tumor-cell programmed death ligand 1 (PD-L1) expression of 1% or greater and then in the overall population (all randomly assigned patients).<h4>Results</h4>A total of 970 patients underwent randomization. At a 13-month minimum follow-up, overall survival was significantly longer with nivolumab plus chemotherapy than with chemotherapy alone, both among patients with tumor-cell PD-L1 expression of 1% or greater (median, 15.4 vs. 9.1 months; hazard ratio, 0.54; 99.5% confidence interval [CI], 0.37 to 0.80; P<0.001) and in the overall population (median, 13.2 vs. 10.7 months; hazard ratio, 0.74; 99.1% CI, 0.58 to 0.96; P = 0.002). Overall survival was also significantly longer with nivolumab plus ipilimumab than with chemotherapy among patients with tumor-cell PD-L1 expression of 1% or greater (median, 13.7 vs. 9.1 months; hazard ratio, 0.64; 98.6% CI, 0.46 to 0.90; P = 0.001) and in the overall population (median, 12.7 vs. 10.7 months; hazard ratio, 0.78; 98.2% CI, 0.62 to 0.98; P = 0.01). Among patients with tumor-cell PD-L1 expression of 1% or greater, a significant progression-free survival benefit was also seen with nivolumab plus chemotherapy over chemotherapy alone (hazard ratio for disease progression or death, 0.65; 98.5% CI, 0.46 to 0.92; P = 0.002) but not with nivolumab plus ipilimumab as compared with chemotherapy. The incidence of treatment-related adverse events of grade 3 or 4 was 47% with nivolumab plus chemotherapy, 32% with nivolumab plus ipilimumab, and 36% with chemotherapy alone.<h4>Conclusions</h4>Both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone in patients with advanced esophageal squamous-cell carcinoma, with no new safety signals identified. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 648 ClinicalTrials.gov number, NCT03143153.).
Citation
The New England journal of medicine, 2022, 386 (5), pp. 449 - 462
Source Title
Publisher
ISSN
0028-4793
eISSN
1533-4406